ous-wave Doppler using the simplified Bernoulli equation.
Based on morphologic and hemodynamic assessments by echocardiography, we divided the patients into the 5 groups: (1) hypertrophic obstructive cardiomyopathy (HOCM), defined as presence of basal LV outflow tract obstruction (gradient ≥30 mmHg at rest), (2) midventricular obstruction (MVO), defined as presence of systolic LV cavity obliteration at the mid ventricle, creating MVO with a peak systolic gradient ≥30 mmHg at rest, (3) dilated phase of HCM (D-HCM), defined as LV systolic dysfunction of the global ejection fraction (EF) <50% (global EF was determined from apical 2-and 4-chamber views; concomitant coronary artery disease was excluded by coronary angiography and/or myocardial scintigraphy), (4) apical HCM, defined as hypertrophy confined to the LV apex, and (5) other (non-obstructive HCM other than D-HCM and apical HCM).
History of major morbid events including (1) hospitalization for heart failure (HF) and (2) embolic complications, including stroke and other systemic embolic events, which occurred as a result of probable or proven embolism was checked at registration.
Data Analysis
Statistical analysis was performed using SPSS (version 14.0) software (SPSS Inc, Chicago, IL, USA). All data are expressed as mean ± SD (range) or frequency (percentage). Differences in continuous variables were assessed using Studentʼs t-test. Pearsonʼs chi-square test was used for comparisons between non-continuous variables, and Fisherʼs exact test was used when the expected frequency was lower than 5. Statistical significance was defined by P≤0.05.
Results

Clinical Characteristics at Registration
The clinical characteristics of the 261 patients at HCM at registration are as follows. Age at registration and at diagnosis was 64±14 (range: 9-88) and 57±15 (range: 6-87) years, respectively, and 173 patients (64%) were men. Approximately half (48%) of the patients were diagnosed symptomatically; 6 were diagnosed as having HCM when embolic stroke occurred and 136 patients (52%) were evaluated because of incidental findings, including ECG abnormalities and systolic murmur, and family screening. Symptoms was present in 171 patients (66%) at diagnosis and in 165 patients (63%) at registration; 64 patients (25%) had proven familial HCM and 45 patients (17%) had a family history of sudden death. At registration, 74 patients (28%) had documented paroxysmal or chronic AF: 35 patients with paroxysmal AF defined as AF expected to convert to sinus rhythm within 7 days of onset, and 39 patients with chronic AF defined as persistent AF for more than 7 days from onset. Three patients received an implantable cardioverterdefibrillator (2 for ventricular fibrillation and 1 for sustained ventricular tachycardia). Of the 261 patients, there were 40 in the HOCM group, 7 in the MVO group, 10 in the D-HCM group, 46 in the apical HCM group, and 158 in the other group. Figure 1 shows the age distribution of the patients and the age-specific prevalence of AF (AF prevalence increased with age). The clinical characteristics of the patients with AF and without AF at registration are shown in Table. Patients with paroxysmal or chronic AF at registration were older than those without AF. Both at diagnosis and registration, patients with AF were more symptomatic (palpitation and dyspnea (New York Heart Association (NYHA) class ≥II)). Furthermore, at registration, most patients (93%) were in NYHA class I or II, and 17 of the 18 patients in NYHA III had AF. Of the 74 patients with AF, 37 (50%) suffered from morbid events (embolism and/or HF admission). Embolic events occurred more frequently in patients with AF at registration than in patients without AF (P< 0.001). In fact, 15 of 19 patients with embolic events (men=17) had AF prior to or at the time of the embolic event; the other 4 patients did not have documented AF despite the occurrence of embolism, and echocardiography revealed that 2 of them had apical aneurysm. Severe HF requiring hospitalization also occurred more frequently in Results of echocardiography at registration showed that LVEDd and left atrial diameters (LAd) were larger and %FS was lower in patients with AF than in patients without AF. There were more D-HCM patients and fewer patients with apical HCM in the AF group. Figures 2 and 3 show the clinical differences in patients who suffered from HCM-related morbid events (embolism or HF admission). In patients with these events, AF was more frequent and LVEDd and LAd were greater and FS lower at registration than in patients without events, and more patients with events were diagnosed as having symptomatic HCM than were patients without events. The 19 patients with cardioembolic events included more men than women. However, there was no gender difference in hospitalization for HF.
Clinical Significance of AF
Distribution of ages at initial documentation of clinical complications is shown in Figure 4 . AF, embolism, and HF admission occurred in patients over 40 years of age. The distribution of the ages of patients with these morbid events is similar to that at the time of initial documentation of AF. Figure 5 shows the period from detection of AF to embolism or HF admission. In the 15 patients with documented AF prior to embolism, embolic events occurred similarly in any period (8 patients had events within 1 year, but 4 of them were diagnosed as having HCM because of embolic events and AF was first detected at that time, indicating that these 4 patients might have suffered from AF for a long time). On the other hand, in the 27 patients with documented AF prior to HF admission, severe HF occurred within 1 year of detecting AF in most of the patients. The majority (95%) of patients with preserved LV systolic function (non-D-HCM patients) were hospitalized for HF within 1 year.
Discussion
HCM is a primary myocardial disorder with heterogeneous clinical and morphologic features. [1] [2] [3] Although most previous studies of this disease, based on populations from largely tertiary referral centers of highly selected patients, have shown a poor prognosis, largely because of sudden cardiac death, recent observations in community-based cohorts in Western countries suggest a more favorable prognosis than that indicated by the results of previous studies. [4] [5] [6] [7] [8] [9] [10] The Kochi Cardiomyopathy Network (the Kochi RYOMA study) was established as a community-based and unselected Japanese patient cohort. In the present report, we provide detailed descriptions of the clinical features of an unselected regional HCM population according to the baseline characteristics at registration in the study. The impact of AF on major morbidity with cardioembolic events and HF admission was again highlighted, as in the previous limited number of existing studies on AF in HCM populations. [12] [13] [14] [15] [16] [17] 
HCM Population
Our regional cohort in the Kochi RYOMA study was older than HCM cohorts in previous studies, [7] [8] [9] [10] [11] 18 probably because Kochi Prefecture, where our study was performed, is located far from urban areas and is one of the most aged communities in Japan. The percentage of male patients in our cohort (64%) was similar to the percentages in previous studies in Western countries and Japan. [7] [8] [9] [10] [11] 18 Although half of the patients were diagnosed because of symptoms, severe functional disability (NYHA class III/IV) was not common in our study. It is notable that embolic stroke was the first clinical manifestation leading to diagnosis of HCM in 6 patients (although ECG abnormalities had been detected in some of those patients, further evaluation had not been performed.). This number of patients was probably an underestimate because patients who died or had severe disability because of embolic events but without the diagnosis of HCM were not included and therefore there should be more patients who had stroke as the initial presentation of this disease. In clinical practice, routine screening by ECG and health education of the general population, as well as screening of HCM family members, plays an important role in preventing not only sudden cardiac death but also embolic stroke causing disability and even death. As for the subtypes of HCM, 40 patients (15%) showed LV outflow obstruction (pressure gradient ≥30 mmHg at rest), a prevalence that was lower than that in cohorts in Western countries. [7] [8] [9] [10] 19 Clinical Impact of AF The reported prevalence of AF in several HCM populations has been approximately 20%, 1, 8, 12, 17, 20 whereas in the present study it was 28% and probably related to the aged cohort. In fact, the prevalence of AF increased with age. Our registration results showed that the prevalence of severe symptoms (NYHA class III/IV) and the frequency of morbid events, including embolism and HF admission, were significantly higher in patients with AF than in those without AF. Compared with the results from referral centers for HCM, there have been several studies showing that a significant portion of patients with HCM in regional cohort populations die from progressive HF and stroke in addition to premature sudden death. 7,21 AF seems to be an important factor for both HCM-related mortality and morbidity. In a recent study of Japanese AF patients, HF requiring hospitalization occurred at a rate of 2% per year and the existence of structural heart disease, including ischemic heart disease, valvular heart disease and cardiomyopathies, was the independent risk factor. 22 The main pathophysiology of HCM is diastolic dysfunction with impaired filling because of abnormal relaxation and increased chamber stiffness, leading in turn to elevated LA and LV end-diastolic pressures. In most HCM patients, the occurrence of AF is considered to be a consequence of progressive diastolic dysfunction and LV remodeling, because in the present study the presence of AF was linked to advanced age, LA and LV enlargement and lower systolic function (%FS).
In our study, the distribution of age at initial documentation of clinical complications showed that AF, embolism and hospitalization for HF occurred similarly after middle age. However, there were different patterns in the period from detection of AF to morbid events, between cardioembolic complications and hospitalization for HF. Embolic events occurred equally at any time between 1 year to 10 years after AF onset, whereas the majority of patients who suffered from HF with preserved LV systolic function (ie, diastolic HF) were hospitalized within 1 year after the occurrence of AF. AF may be responsible for relatively acute progression of HF, resulting from reduced diastolic filling and cardiac output as a consequence of loss of atrial contraction to LV filling and increased ventricular rate under conditions of LVH with preexisting impaired relaxation and compliance.
Study Limitations
We have presented the clinical features of HCM in a prospectively assembled, community-based and unselected patient cohort in a regional Japanese population, based on baseline characteristics at registration. Clinical complications including AF, embolic events, and hospitalization for HF were evaluated retrospectively. Furthermore, although morbid events occurred more frequently in patients with AF than in those without AF, half of the patients with AF did not suffer from morbid events. Therefore, further studies of the outcome, prognosis and prognostic factors in patients with HCM from the follow-up data in the Kochi RYOMA study are needed.
Conclusions
In our unselected regional registry, AF was the major determinant of clinical deterioration, including hospitalization for HF, as well as embolic events, in patients with HCM. Of note, diastolic HF within 1 year of the detection of AF
